# US 2021/0079102 A1 · Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079102 A1
- Document ID: US20210079102A1
- Status: Published application
- Kind: A1
- Application number: 16/967,218
- Filed: 2019-02-08
- Published: 2021-03-18
- Earliest claimed: 2018-02-08
- Assignees: Dragonfly Therapeutics, Inc.
- Applicants: Dragonfly Therapeutics, Inc.
- Inventors: Gregory P. Chang; Ann F. Cheung; Asya Grinberg; Eva Gutierrez; William Haney; Nicolai Wagtmann; Bradley M. Lunde; Bianka Prinz
- Web page: https://patentgrep.com/patent/US20210079102A1

## CPC

- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/2013: {IL-2}
- A61K 38/208: {IL-12}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 39/0011: {Cancer antigens}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/4221: {CD20}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2887: {against CD20}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2239/57: Skin; melanoma
- C07K 14/55: IL-2
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2319/03: containing a transmembrane segment
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

## Claims

### Claim 1

A method of enhancing tumor cell death directly or indirectly, the method comprising exposing a tumor and natural killer cells to a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer targeted agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:47 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:48.

### Claim 2

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
or a formulation comprising the protein;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer target agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:47 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:48.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the heavy chain variable domain comprises a complementarity-determining region 1 (CDR1) sequence represented by the amino acid sequence of SEQ ID NO:92, a complementarity-determining region 2 (CDR2) sequence represented by the amino acid sequence of SEQ ID NO:58, and a complementarity-determining region 3 (CDR3) sequence represented by the amino acid sequence of SEQ ID NO:113; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:60, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:61, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:62.

### Claim 4 (depends on 3)

The method of claim 3, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:92, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:58, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:93; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:60, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:61, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:62.

### Claim 5 (depends on 3)

The method of claim 3, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:57, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:58, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:59; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:60, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:61, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:62.

### Claim 6 (depends on 3)

The method of claim 3, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:92, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:58, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:104; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:60, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:61, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:62.

### Claim 7 (depends on 3)

The method of claim 3, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:57, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:58, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:103; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:60, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:61, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:62.

### Claim 8

A method of enhancing tumor cell death directly or indirectly, the method comprising exposing a tumor and natural killer cells to a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer targeted agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:45 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:46.

### Claim 9

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
or a formulation comprising the protein;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer target agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:45 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:46.

### Claim 10 (depends on 8, 9)

The method of claim 8 or 9, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:90, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:52, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:91; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:54, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:55, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:56.

### Claim 11 (depends on 8, 9)

The method of claim 8 or 9, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:51, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:52, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:53; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:54, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:55, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:56.

### Claim 12

A method of enhancing tumor cell death directly or indirectly, the method comprising exposing a tumor and natural killer cells to a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer targeted agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:49 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:50.

### Claim 13

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
or a formulation comprising the protein;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer target agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:49 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:50.

### Claim 14 (depends on 12, 13)

The method of claim 12 or 13, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:94, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:64, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:95; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:66, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:67, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:68.

### Claim 15 (depends on 12, 13)

The method of claim 12 or 13, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:63, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:64, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:65; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:66, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:67, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:68.

### Claim 16

A method of enhancing tumor cell death directly or indirectly, the method comprising exposing a tumor and natural killer cells to a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer targeted agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:114 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:115.

### Claim 17

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
or a formulation comprising the protein;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer target agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:114 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:115.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:122, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:117, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:123; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:119, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:120, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:121.

### Claim 19 (depends on 16, 17)

The method of claim 16 or 17, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:116, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:117, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:118; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:119, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:120, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:121.

### Claim 20

A method of enhancing tumor cell death directly or indirectly, the method comprising exposing a tumor and natural killer cells to a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer targeted agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:124 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:125.

### Claim 21

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
or a formulation comprising the protein;
in combination with a second therapeutic agent selected from: a checkpoint blocker, a cytokine, a TLR agonist, a STING agonist, a chemotherapeutic agent, a cancer target agent, an oncolytic virus, a vaccine, radiation, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence,
wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, the heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:124 and the light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:125.

### Claim 22 (depends on 20, 21)

The method of claim 20 or 21, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:122, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:117, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:130; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:127, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:128, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:129.

### Claim 23 (depends on 20, 21)

The method of claim 20 or 21, wherein the heavy chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:116, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:117, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:126; and the light chain variable domain comprises a CDR1 sequence represented by the amino acid sequence of SEQ ID NO:127, a CDR2 sequence represented by the amino acid sequence of SEQ ID NO:128, and a CDR3 sequence represented by the amino acid sequence of SEQ ID NO:129.

### Claim 24

A method of enhancing tumor cell death directly or indirectly, the method comprising exposing a tumor and natural killer cells to a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
in combination with a second therapeutic agent selected from: a TLR agonist, a STING agonist, an oncolytic virus, a vaccine, an adoptive NK therapy, a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence.

### Claim 25

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds a tumor-associated antigen; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16;
or a formulation comprising the protein;
in combination with a second therapeutic agent selected from: a TLR agonist, a STING agonist, an oncolytic virus, a vaccine, an adoptive NK therapy, and a stem cell transplant (SCT) therapy, a chimeric antigen receptor (CAR) T cell therapy, and an agent that induces cellular senescence.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the checkpoint blocker is selected from: an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, an anti-KIR antibody, an anti-NKG2A antibody, an anti-LAG3 antibody, and an anti-TIM3 antibody.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the cytokine is selected from: IL-2, IL-15, IL-12, INFα, IL-21, PEG-IL-2 and IL15/IL15R heterodimers.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the TLR agonist is selected from a TLR7 agonist, a TLR8 agonist, a TLR7/8 agonist, a TLR9 agonist, a TLR4 agonist, and a TLR3 agonist.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the STING agonist is ADU-S100.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the chemotherapeutic agent is paclitaxel, nab-paclitaxel or cyclophosphamide.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the checkpoint blocker is selected from: nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab, tremelimumab, lirilumab, and monalizumab.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the TLR agonist is selected from: R848/resiquimod, VTX-2337, imiquimod, and CpG oligodeoxynucleotide.

### Claim 33 (depends on 2, 3, 4, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19)

The method of any one of claims 2-7, 9-11, 13-15, 17-19, and 21-32, wherein the cancer is selected from the group consisting of acute myeloid leukemia, acute myelomonocytic leukemia, B cell lymphoma, bladder cancer, breast cancer, colorectal cancer, diffuse large B cell lymphoma esophageal cancer, Ewing's sarcoma, follicular lymphoma, gastric cancer, gastrointestinal cancer, gastrointestinal stromal tumors, glioblastoma, head and neck cancer, melanoma, mesothelioma, multiple myeloma, myelodysplastic syndrome, renal cell carcinoma, neuroblastoma, non-small cell lung cancer, neuroendocrine tumors, ovarian cancer, and pancreatic cancer, prostate cancer, sarcomas, small cell lung cancer, T cell lymphoma, testis cancer, thymic carcinoma, thyroid cancer, urothelial cancer, cancers infiltrated by myeloid-derived suppressor cells, cancers with extracellular matrix deposition, cancers with high levels of reactive stroma, and cancers with neoangiogenesis.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the first antigen-binding site of the protein binds to NKG2D in humans, non-human primates, and rodents.

### Claim 35 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 24-34, wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the heavy chain variable domain and the light chain variable domain are present on the same polypeptide.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the second antigen-binding site also comprises a heavy chain variable domain and a light chain variable domain.

### Claim 38 (depends on 37)

The method of claim 37, wherein the light chain variable domain of the first antigen-binding site has an amino acid sequence identical to the amino acid sequence of the light chain variable domain of the second antigen-binding site.

### Claim 39 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 24-34, wherein the first antigen-binding site is a single-domain antibody.

### Claim 40 (depends on 39)

The method of claim 39, wherein the single-domain antibody is a VHH fragment or a VNAR fragment.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39)

The method of any one of claims 1-36, 39, and 40, wherein the second antigen-binding site is a single-domain antibody.

### Claim 42 (depends on 41)

The method of claim 41, wherein the second antigen-binding site is a VHH fragment or a VNAR fragment.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 1-40, wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 1-43, wherein the tumor-associated antigen is selected from the group consisting of EpCAM, CD2, CD19, CD20, CD30, CD38, CD40, CD52, CD70, EGFR/ERBB1, IGF1R, HER3/ERBB3, HER4/ERBB4, MUC1, cMET, SLAMF7, PSCA, MICA, MICB, TRAILR1, TRAILR2, MAGE-A3, B7.1, B7.2, CTLA4, and PD-L1.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the protein comprises a portion of an antibody Fc domain sufficient to bind CD16, wherein the antibody Fc domain comprises hinge and CH2 domains.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the protein comprises an amino acid sequence at least 90% identical to amino acids 234-332 of a human IgG1 antibody.

### Claim 47 (depends on 2, 3, 4, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19)

The method of any one of claims 2-7, 9-11, 13-15, 17-19, and 21-46, wherein the formulation further comprises a pharmaceutically acceptable carrier.
